HWI Pharma Services

HWI Pharma Services is a well-established, privately-held German CDMO and service provider offering integrated solutions from early-stage development through to lifecycle management. The company's core strengths lie in its comprehensive analytical capabilities, formulation development for complex APIs (including high-potent compounds up to OEB5), and flexible small-batch manufacturing for clinical and commercial supply. Operating as a service-based business, HWI generates revenue by providing these specialized technical and regulatory services to pharmaceutical and biotech clients, positioning itself as a one-stop partner for drug development programs, particularly in the European market.

Integrated service platform for pharmaceutical development and manufacturing, including formulation development for complex APIs (high-potent, poorly soluble), advanced analytical sciences, clinical & small-batch GMP manufacturing, and digitalized pharmacovigilance services.

HWI operates in the highly competitive global CDMO and CRO market. It competes with large, full-service players like Lonza and Catalent, as well as numerous specialized European CDMOs. Its differentiation lies in its integrated end-to-end model for small to medium batches, deep analytical expertise, and focus on complex formulation challenges.